BNTC

Benitec Biopharma, Inc.distress 3/10 · well-funded / low risk

$11.36-1%today-31% from 52w high

benitec.com19 employeesHayward, CABiotechnology

Lead: Oculopharyngeal Muscular Dystrophy

Revenue

pre-revenue

Liquidity

$185M

Runway

7.8 yrs

Shares 1y

+31%

Price & events

-11.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.7%

-10.3%

-11.8%

-10.6%

-9.0%

-4.1%

+26.4%

-82.3%

-80.0%

All

Overview

Market Cap: $390.27M
Volume: 4.23K
52 Week Range: $10.06 – $16.52
Total Shares: 34.35M
Float Shares: 17.93M
Short %: 11.48%
% Held by Insiders: 2.55%
% Held by Institutions: 98.31%
RVOL: 0.03x
Beta: 0.25

Pipeline stages · 1 programs

BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-3

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2030-11

Pipeline · 1 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2030-11 Estimated 50% readout ~2030-12-16	Phase 1/2	BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-3fast trackorphan	Oculopharyngeal Muscular Dystrophy	—	recruiting

Catalyst news & presentations · 5

2026-09-22earningsEarningsEarnings releaseyahoo
Q4 2025trial initiationsecondaryPhase 1/2BB-301 · Enrollment of Cohort 2 expected to beginSEC 8-K
November 3, 2025conferencedata presentationsecondaryBB-301 · Live webcast of latest interim clinical data presentationSEC 8-K
first quarter of calendar 2025conferencedata presentationsecondaryPhase 1/2BB-301 · Additional interim clinical study results at medical conferences and company webcasts.SEC 8-K
this monthtrial initiationsecondaryPhase 1/2BB-301 · Third subject to be treated with low-dose BB-301SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 34,354,334 · 3 offerings/1y · 0 PIPEs

2026-02-11424B3offering
2026-02-10EFFECTshelf_effective
2026-01-30S-3shelf_registration
2025-11-078-Kmaterial_agreement
2025-11-07424B5offering
2025-11-05424B5offering
2025-09-29EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $26 (+127% upside) · 5 analysts

2026-05-12Evercore ISI GroupOutperform
2026-03-09HC Wainwright & Co.Buy
2025-11-24HC Wainwright & Co.Buy
2025-11-04HC Wainwright & Co.Buy
2025-11-04CitizensMarket Outperform
2025-09-24JMP SecuritiesMarket Outperform

Competitors — Oculopharyngeal Muscular Dystrophy

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.